ARTICLE | Company News
University of Pittsburgh, Oxis deal
September 21, 2015 7:00 AM UTC
The partners amended a January deal granting Oxis’ Oxis Biotech Inc. subsidiary exclusive, worldwide rights to develop and commercialize P62 chemical agents to treat multiple myeloma (MM) to include ...